Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
154 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Newborn screening of neuromuscular diseases.
Dangouloff T, Boemer F, Servais L · Neuromuscul Disord · 2021Systematic Review
- AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.
Ma X, Zhuang L, Ma W, et al. · N Engl J Med · 2025Clinical Trial, Phase I
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, et al. · J Med Genet · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Karaa A, Bertini E, Carelli V, et al. · Neurology · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Physical training for McArdle disease.
Quinlivan R, Vissing J, Hilton-Jones D, et al. · Cochrane Database Syst Rev · 2011Systematic Review
- Significance of Asymptomatic Hyper Creatine-Kinase Emia.
Finsterer J, Scorza FA, Scorza CA · J Clin Neuromuscul Dis · 2019Systematic Review
- The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
Kronn D, Davison J, Broomfield A, et al. · J Pediatr · 2025Clinical Trial, Phase II, Multicenter Study
- Spectrum and frequencies of extraocular features reported in CEP290-associated ciliopathy - A systematic review.
Vrabič N, Fakin A, Tekavčič Pompe M · J Fr Ophtalmol · 2024Systematic Review
- Observational and experimental studies on sleep duration and aggression: A systematic review and meta-analysis.
Van Veen MM, Lancel M, Şener O, et al. · Sleep Med Rev · 2022Meta-Analysis, Systematic Review
- Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.
Kishnani PS, Díaz-Manera J, Illarioshkin S, et al. · J Neurol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Global birth prevalence of Pompe disease: A systematic review and meta-analysis.
Kong W, Lu C, Wang L · Neuroscience · 2024Systematic Review, Meta-Analysis
- On Patients Who Purchase Organ Transplants Abroad.
Ambagtsheer F, de Jong J, Bramer WM, et al. · Am J Transplant · 2016Systematic Review
- Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease.
Tan L, Zschüntzsch J, Meyer S, et al. · Nat Commun · 2024Research Support, Non-U.S. Gov't, Clinical Trial
- Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer.
Gild P, Pompe RS, Seisen T, et al. · Eur Urol Oncol · 2021Randomized Controlled Trial
- Enzyme replacement therapy for the treatment of late onset Pompe disease: A systematic review and network meta-analysis.
Corbett M, Umemneku-Chikere C, Nevitt S, et al. · Orphanet J Rare Dis · 2025Systematic Review, Network Meta-Analysis
- External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer.
Pompe RS, Karakiewicz PI, Zaffuto E, et al. · J Sex Med · 2017Clinical Trial, Phase II, Clinical Trial, Phase III
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.
Berger KI, Ivanescu C, Msihid J, et al. · J Neuromuscul Dis · 2025Clinical Trial, Phase III, Multicenter Study
- Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R, Martinuzzi A, Schoser B · Cochrane Database Syst Rev · 2014Meta-Analysis, Systematic Review
- Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B, Giovanna B, Emanuela K, et al. · J Neurol · 2022Meta-Analysis, Systematic Review
- In situ decompression vs conservative treatment for mild ulnar neuropathy at the elbow.
Pompe SM, Schreuder T, Teunissen LL, et al. · Muscle Nerve · 2020Randomized Controlled Trial
- Cardiovascular disease in non-classic Pompe disease: A systematic review.
van Kooten HA, Roelen CHA, Brusse E, et al. · Neuromuscul Disord · 2021Systematic Review
- [What is the REAL long-term risk of proton pump inhibitors?].
Ribiere S, Guillaumot MA, Barré A, et al. · Presse Med · 2019Systematic Review
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, et al. · Lancet Neurol · 2021Multicenter Study, Randomized Controlled Trial
- Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study.
Rosales RL, Balcaitiene J, Berard H, et al. · Toxins (Basel) · 2018Clinical Trial, Phase IV, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.